Compare Freeport-McMoRan Inc (FCX) vs Humana Inc (HUM) Price & Performance

Freeport-McMoRan (FCX) trades at $71.87, down 0.97% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected shortly. FCX maintains solid profitability with 11.38% net margin and 15.37% ROE, supported by robust operational cash flow of $5.61 billion in 2025. Recent news highlights copper's strategic importance for AI infrastructure, positioning FCX to benefit from long-term demand trends.

FCX presents a compelling opportunity with analyst consensus at Buy (61%) and $73.27 price target, offering 2% upside. The company's expansion projects and copper's AI-driven demand create growth potential, though rising production costs and ongoing legal investigation pose risks. Institutional sentiment remains positive given FCX's market leadership and favorable commodity outlook.

Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.

The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.